Kimberly-Clark Corporation: Q2 2024 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2024. Kimberly-Clark Corporation (KMB) operates three reportable segments: Personal Care, Consumer Tissue, and K-C Professional. The company is currently executing a 2024 Transformation Initiative announced in March 2024, aimed at reorganizing into three new business segments, optimizing the supply chain, and reducing the structural cost base. The initiative anticipates total pre-tax costs of approximately $1.5 billion, with completion expected by the end of 2026.
Key Financial Metrics
| Metric (in millions, except per share) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Sales | $5,029 | $5,134 | $10,178 | $10,329 |
| Gross Profit | $1,810 | $1,731 | $3,721 | $3,457 |
| Operating Profit | $655 | $113 | $1,508 | $900 |
| Net Income (Attributable to K-C) | $544 | $102 | $1,191 | $668 |
| Diluted EPS | $1.61 | $0.30 | $3.52 | $1.97 |
| Cash from Operations (YTD) | $1,459 | $1,400 | $1,459 | $1,400 |
| Total Debt | $7,964 | $7,984 | $7,964 | $7,984 |
| Cash & Equivalents | $1,163 | $580 | $1,163 | $580 |
Note: Total Debt includes $806 million current and $7,158 million long-term as of June 30, 2024.
Material Changes vs. Prior Period
- Profitability Surge: Operating profit increased 480% year-over-year in Q2 ($655M vs. $113M). This significant jump is primarily due to a $658 million impairment charge recorded in Q2 2023 related to the Softex Indonesia and Thinx businesses, which did not recur in 2024.
- Revenue Decline: Net sales decreased 2% in Q2 and 1% YTD. Organic sales grew 4% in Q2 and 5% YTD, driven by pricing and volume, but were offset by a 5% negative impact from foreign currency translation and 1% from divestitures (Brazil tissue business).
- Transformation Costs: Q2 2024 results include $190 million in pre-tax charges related to the 2024 Transformation Initiative (workforce reductions, asset write-offs, and exit costs). YTD charges totaled $235 million.
- Segment Performance:
- Personal Care: Sales flat; Operating profit up 14% (Q2) and 13% (YTD) due to volume, mix, and productivity.
- Consumer Tissue: Sales down 4% (Q2) due to divestitures and organic declines; Operating profit up 23% (Q2) driven by productivity savings.
- K-C Professional: Sales down 5% (Q2); Operating profit flat. Organic sales were flat as mix gains offset lower pricing and volume.
Outlook, Risks, and Unusual Items
- Divestiture: On July 1, 2024, the company completed the sale of its personal protective equipment (PPE) business (Kimtech and KleenGuard brands) for $640 million. A gain is expected to be recognized in Q3 2024.
- Transformation Outlook: The company expects to complete the organizational transition by end of 2024. Total pre-tax savings are projected at $3.0 billion in gross productivity plus $200 million in SG&A savings.
- Geopolitical Risks: Operations in Russia (approx. 1-2% of global sales) remain limited to essential items. The company faces risks regarding asset impairment, supply chain restrictions, and sanctions. High inflation in Argentina and Turkey continues to impact currency translation.
- Capital Allocation: The company repurchased 1.2 million shares for $159 million in the first half of 2024. Full-year capital spending is anticipated to be approximately $800 million.
Investor Verification Checklist
- Non-GAAP Reconciliation: Verify the "Adjusted" operating profit and EPS figures, which exclude the 2024 Transformation Initiative charges ($190M Q2) and the 2023 impairment/divestiture impacts, to understand underlying operational trends.
- Organic Growth Drivers: Confirm the sustainability of the 4-5% organic sales growth, noting it is heavily influenced by pricing in hyperinflationary economies (Argentina) rather than pure volume expansion in all regions.
- Transformation Execution: Monitor the realization of the projected $3.0 billion in productivity savings against the $1.5 billion in implementation costs over the next two years.
- Currency Exposure: Assess the impact of the 5% currency headwind on future earnings, particularly given the volatility in Emerging Markets.
- PPE Divestiture Gain: Watch for the recognition of the gain from the $640 million PPE sale in the Q3 2024 earnings report.